MUMBAI, India, Feb. 27 -- Intellectual Property India has published a patent application (202541132835 A) filed by Gautham S; Mari Maheshwaran. B; Mohana Priyan. K; Suriya. G; and Jenstina J, Coimbatore, Tamil Nadu, on Dec. 29, 2025, for 'corn silk glutelin as a novel excipient : binder and disintegrant roles in solid dosage forms.'
Inventor(s) include Gautham S; Mari Maheshwaran. B; Mohana Priyan. K; Suriya. G; and Jenstina J.
The application for the patent was published on Feb. 27, under issue no. 09/2026.
According to the abstract released by the Intellectual Property India: "Corn silk, a common agricultural by-product, is increasingly recognised as a sustainable source of plant proteins and bioactive compounds, but its application in solid oral dosage forms has received little focused attention. In this study, glutelin-rich protein fractions were isolated from corn silk and evaluated as a dual-function excipient in tablet formulations, with the intention of replacing part of the conventional maize starch and synthetic binders in a more eco-friendly way. The purified corn silk glutelin showed reliable film-forming behaviour, adequate cohesive strength during compression, and rapid swelling in aqueous media, features that supported both strong granule binding and efficient tablet breakup after hydration. In simple model formulations, tablets containing corn silk glutelin displayed mechanical strength and disintegration times on par with starch-based systems that are routinely employed as binders and disintegrants in pharmaceutical tablets. Using corn silk that would normally be discarded adds value to this low-cost biomass and introduces a bio-based excipient with relatively low patent saturation, consistent with current efforts in sustainable excipient design and circular bioeconomy. Taken together, these observations indicate that corn silk glutelin is a practical and promising multifunctional excipient for greener solid dosage forms and justifies further work on process optimisation, scale-up, and regulatory evaluation for future pharmaceutical use."
Disclaimer: Curated by HT Syndication.
